Suivi à 2 ans d'une cohorte de patients sous buprénorphine haut dosage. Résultats de l'étude SPESUB (suivi pharmaco-épidémiologique du Subutex® en médecine de ville)
- Other title
- Two years follow-up of heroin users treated by GPs with high dosage buprenorphine : the SPESUB study (pharmaco-epidemiological follow-up of high dosage buprenorphine in general practice) (en)
- Author
- DUBURCQ, A1 ; CHARPAK, Y1 ; BLIN, P1 ; MADEC, L1
[1] EVAL, 43, boulevard du Maréchal Joffre, 92340 Bourg-la-Reine, France - Source
Revue d'épidémiologie et de santé publique. = Epidemiology and public health. 2000, Vol 48, Num 4, pp 363-373 ; ref : 32 ref
- Publisher
- Masson, Paris
- Publication country
- France
- Document type
- Article
- Language
- French
- Keyword (fr)
- Buprénorphine Chimiothérapie Dose forte Etude cohorte Homme Opiacés Toxicomanie Traitement
- Keyword (en)
- Buprenorphine Chemotherapy High dose Cohort study Human Opiates Drug addiction Treatment
- Keyword (es)
- Buprenorfina Quimioterapia Dosis fuerte Estudio cohorte Hombre Opiados Toxicomanía Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology / 002B02B11 Miscellaneous
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1482440
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Revue d'\u00e9pid\u00e9miologie et de sant\u00e9 publique\";s:9:\"\u0000*\u0000stitle\";s:33:\"Rev. \u00e9pid\u00e9miol. sant\u00e9 publique\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"363\";s:8:\"\u0000*\u0000epage\";s:3:\"373\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0398-7620\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DUBURCQ\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:10:\"CHARPAK, Y\";i:1;s:7:\"BLIN, P\";i:2;s:8:\"MADEC, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:8:\"\u0000*\u0000place\";s:5:\"Paris\";s:6:\"\u0000*\u0000pub\";s:6:\"Masson\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Revue d'\u00e9pid\u00e9miologie et de sant\u00e9 publique\";s:9:\"\u0000*\u0000stitle\";s:33:\"Rev. \u00e9pid\u00e9miol. sant\u00e9 publique\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"363\";s:8:\"\u0000*\u0000epage\";s:3:\"373\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0398-7620\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DUBURCQ\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:10:\"CHARPAK, Y\";i:1;s:7:\"BLIN, P\";i:2;s:8:\"MADEC, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:8:\"\u0000*\u0000place\";s:5:\"Paris\";s:6:\"\u0000*\u0000pub\";s:6:\"Masson\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Revue d'\u00e9pid\u00e9miologie et de sant\u00e9 publique\";s:9:\"\u0000*\u0000stitle\";s:33:\"Rev. \u00e9pid\u00e9miol. sant\u00e9 publique\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"363\";s:8:\"\u0000*\u0000epage\";s:3:\"373\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0398-7620\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DUBURCQ\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:10:\"CHARPAK, Y\";i:1;s:7:\"BLIN, P\";i:2;s:8:\"MADEC, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:8:\"\u0000*\u0000place\";s:5:\"Paris\";s:6:\"\u0000*\u0000pub\";s:6:\"Masson\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Revue d'\u00e9pid\u00e9miologie et de sant\u00e9 publique\";s:9:\"\u0000*\u0000stitle\";s:33:\"Rev. \u00e9pid\u00e9miol. sant\u00e9 publique\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"363\";s:8:\"\u0000*\u0000epage\";s:3:\"373\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0398-7620\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DUBURCQ\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:10:\"CHARPAK, Y\";i:1;s:7:\"BLIN, P\";i:2;s:8:\"MADEC, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:8:\"\u0000*\u0000place\";s:5:\"Paris\";s:6:\"\u0000*\u0000pub\";s:6:\"Masson\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Revue d'\u00e9pid\u00e9miologie et de sant\u00e9 publique\";s:9:\"\u0000*\u0000stitle\";s:33:\"Rev. \u00e9pid\u00e9miol. sant\u00e9 publique\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"363\";s:8:\"\u0000*\u0000epage\";s:3:\"373\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0398-7620\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DUBURCQ\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:10:\"CHARPAK, Y\";i:1;s:7:\"BLIN, P\";i:2;s:8:\"MADEC, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"Suivi \u00e0 2 ans d'une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l'\u00e9tude SPESUB (suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville)\";s:8:\"\u0000*\u0000place\";s:5:\"Paris\";s:6:\"\u0000*\u0000pub\";s:6:\"Masson\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
